Levosimendan is indicated for the short-term treatment of acute severe decompensation of chronic heart failure in situations where conventional treatment is not sufficient, and in cases where inotropic support is considered appropriate.
Much higher therapeutic adherence
Very wide antibiotic spectrum of action
Activity against Neisseria meningitidis.
Used to treat multidrug-resistant.
Better pharmacokinetic profile.
Longer half-life than Tetracycline.
FDA and European approval for the treatment of infections.
Low development of resistance in bacteria.
Concentrate for solution for infusion:
2,5 mg/ml
USD global market sales in 2023
consumed globally
Lorem ipsum solor
PATENT PROTECTION